Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 12, 2026
TickeronGET DAILY SIGNALS
Cingulate (CING) Analyst Targets Average $24, Pointing to a Potential +435% Move

Cingulate (CING) Analyst Targets Average $24, Pointing to a Potential +435% Move

Key Takeaways

  • The central target of $24 represents the arithmetic mean of three current analyst price targets for Cingulate Inc. (CING), a clinical-stage biopharmaceutical company.
  • With shares recently trading near $4.49, reaching $24 would require a roughly 435% advance, a substantial move for any equity.
  • Individual targets range widely from $9 (ROTH Capital Partners) to $44 (Ascendiant Capital), highlighting significant disagreement on the value of Cingulate's ADHD pipeline.
  • The bull case centers on CTx-1301, a Phase 3 dexmethylphenidate candidate built on the company's Precision Timed Release (PTR) delivery platform.
  • Key risks include the lack of revenue, ongoing cash burn, potential regulatory setbacks on the lead program, and the dilutive financing typical for pre-commercial biotechs.
  • Investors can review the company's Major News, Today's Price Move, Forecast, and Earnings on additional pages for updated detail.
  • For a broader, data-driven view of market opportunities, readers can explore Trending AI Robots.

Analyst Price Targets and Consensus View

Cingulate Inc. (CING) is a micro-cap, clinical-stage biopharmaceutical company headquartered in Kansas City, Kansas, focused on treatments for attention-deficit/hyperactivity disorder (ADHD) and anxiety through its PTR drug-delivery platform. The company currently has no product revenue and relies on cash reserves and capital raises to fund operations. I reviewed three current, individually attributable analyst targets. Ascendiant Capital's Edward Woo reduced his 12-month target from $52 to $44 while keeping a Buy rating on August 20, 2026, based on a net-present-value (NPV) analysis. H.C. Wainwright reiterated a Buy with a $20 target on May 26, 2026. ROTH Capital Partners maintained a Buy but lowered its target to $9 on August 24, 2026. The arithmetic mean of $44, $20, and $9 comes to approximately $24.33, which rounds to $24. The $9-to-$44 range stands out as unusually wide, underscoring that these are probability-weighted estimates for an unproven pipeline rather than firm predictions. All three firms hold Buy ratings, yet the nearly fivefold spread illustrates how sensitive the forecast remains to assumptions around regulatory success, market size, and future dilution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With shares recently trading near $4.49, reaching the $24 central target would imply upside of roughly 435%, a very large move. Cingulate's market capitalization sits at approximately $65 million, and the stock has traded between $3.16 and $11.89 over the past 52 weeks. The path to materially higher prices depends almost entirely on clinical and regulatory execution. The lead candidate, CTx-1301 (dexmethylphenidate), remains in Phase 3 development for ADHD across pediatric, adolescent, and adult populations. Without commercial revenue, valuation hinges on binary milestones such as trial data readouts, resubmission decisions, and potential approval. Each positive step could re-rate the stock sharply, while setbacks could compress it equally fast.

What Could Support a Move Toward the Target

  • Addressable market: ADHD represents a large, established treatment category, and a differentiated once-daily, precision-timed stimulant could attract meaningful commercial interest.
  • PTR platform: The erosion-barrier delivery technology aims to deliver predictable, time-dependent drug release, offering a potential edge in an ADHD market attuned to side effects and dosing convenience.
  • Analyst conviction: All three tracked firms maintain Buy ratings despite the wide target dispersion, pointing to fundamental optimism about the pipeline's long-term value.
  • Financial runway: The company has reported cash on hand in the tens of millions with minimal debt, although future capital raises appear likely.

What Could Prevent the Target From Being Reached

  • Regulatory risk: Market commentary has noted an FDA Complete Response Letter (CRL) on the lead program, a development that weighs on sentiment and delays any approval timeline.
  • No revenue and recurring losses: With negative earnings per share (EPS) and no commercial sales, Cingulate depends on continued financing to advance trials.
  • Dilution: Expanding the equity incentive pool and raising capital for Phase 3 studies can meaningfully dilute existing shareholders.
  • Micro-cap volatility: Low float and modest average volume can lead to outsized swings, complicating sustained price appreciation without durable fundamental news.

Technical Levels and Market Structure

Cingulate's price remains below its 50-day and 200-day moving averages, near $4.88 and $5.40 respectively, reflecting a downtrend from earlier 2026 highs. The 52-week low of $3.16, reached in mid-2026, serves as the key support level to monitor, while the 52-week high of $11.89 stands as major overhead resistance. Round-number levels near $5 and $10 act as additional psychological barriers, and any sustainable advance toward the $24 target would first require reclaiming and holding above $11.89, the prior peak.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, and Ascendiant's latest note specifically references a 12-month target, though horizons can vary. Investors should track upcoming quarterly results for cash burn and financing updates, clinical and regulatory developments on CTx-1301, any resubmission strategy after the CRL, analyst target revisions, and broader biotechnology-sector risk appetite. Each factor could shift the probability-weighted value embedded in the $9-to-$44 target range.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs continuously, producing Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. For a low-float, event-driven name like Cingulate, such tools can assist traders in identifying shifting trends, uncovering new opportunities, and overseeing existing positions more efficiently than manual review alone.

Final Assessment

The $24 central target reflects the arithmetic mean of three widely dispersed analyst targets rather than a consensus that Cingulate will trade at that level. From roughly $4.49, the required move remains very large, and the $9-to-$44 spread reveals limited agreement on the company's fair value. The strongest supports lie in the Phase 3 CTx-1301 program and the PTR platform's differentiation, while the main obstacles include a regulatory setback, the absence of revenue, ongoing losses, and likely dilution. A move toward $24 would hinge overwhelmingly on clinical and regulatory execution rather than valuation re-rating alone. No outcome is guaranteed, and investors should monitor trial data, financing updates, and analyst revisions closely before drawing conclusions.

Exploring AI Tools for Deeper Analysis

In my own research process, I often turn to Tickeron's AI Daily Buy/Sell Signals to supplement traditional analysis. The platform uses AI to scan market data in real time and flag potential entry or exit points across a wide range of securities. For names like Cingulate that move on clinical news, these signals can provide an additional layer of perspective on momentum shifts. The toolset also includes pattern recognition and trend prediction features that help quantify risk-reward scenarios without replacing fundamental due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CING

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CING's Stochastic Oscillator dives oversold zone

The Stochastic Oscillator for CING moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where CING advanced for three days, in 193 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for CING moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 17 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CING as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for CING turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 40 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

CING moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CING crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CING declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CING broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CING entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CING’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (-1.197) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CING’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
1901 West 47th Place
Phone
+1 913 942-2300
Employees
14
Web
https://www.cingulate.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.